HUMAN-ANTIBODIES TO RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH HYPERNEPHROMA
HUMAN-ANTIBODIES TO RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH HYPERNEPHROMA
复制标题
DOI：
10.1089/jir.1994.14.177
复制
发表时间：
1994-08-01
期刊：
影响因子：
--
通讯作者：
POLIWODA, H
中科院分区：
文献类型：
--
作者：
ATZPODIEN, J;HANNINEN, EL;POLIWODA, H
阿姆斯特丹），皮下给药，在76例进行性转移性疾病的肾上腺瘤患者。试验了四种不同的治疗方案，分别是单独使用rIL-2、递增剂量或脉冲剂量，或与肿瘤细胞疫苗或重组IFN-α 2b-γ联合使用。用标准的Western blot技术证实了它们的特异性。在标准小鼠CTLL细胞增殖试验中进行血清抗体中和rIL-2的试验。可溶性IL-2受体和表达CD 56自然杀伤细胞的淋巴细胞亚群的血清水平
Amsterdam), given subcutaneously, in 76 hypernephroma patients with progressive metastatic disease. Four different treatment regimens were tried, with, respectively, rIL-2 used alone, given in escalatingdoses, or as pulsed doses; or used in combina-tion with a tumor cell vaccine, or recombinant IFN-a2b-*') Sera from patients were screened for the development of non-neutralizing antibodies against rIL-2 in an enzyme-linked immunosorbent assay. Their specificity was confirmed by a stan-dard Western blot technique. Tests for serum antibodies neutralizing rIL-2 were carried out in a standard mouse CTLL cell proliferation assay. Serum levels of soluble IL-2 receptors and of lymphocyte subsets expressing the CD56 natural killer